PubRank

Jeffrey S Ross

Author PubWeight™ 145.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003 32.01
2 Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005 9.70
3 Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013 7.97
4 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006 7.24
5 Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012 6.77
6 Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005 4.03
7 The high-field-strength curmudgeon. AJNR Am J Neuroradiol 2004 2.83
8 Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005 2.29
9 Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005 2.16
10 Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007 1.95
11 MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009 1.89
12 Lumbar degenerative disk disease. Radiology 2007 1.88
13 Acute low back pain and radiculopathy: MR imaging findings and their prognostic role and effect on outcome. Radiology 2005 1.80
14 Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol 2013 1.71
15 TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 2011 1.68
16 Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012 1.66
17 Localized lymphedema (elephantiasis): a case series and review of the literature. J Cutan Pathol 2008 1.66
18 BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 2013 1.66
19 Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006 1.61
20 Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther 2014 1.57
21 Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2013 1.54
22 Spine infection/inflammation. Radiol Clin North Am 2011 1.40
23 Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol 2014 1.38
24 Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009 1.31
25 Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006 1.30
26 The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 2007 1.26
27 Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 2005 1.25
28 Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 2009 1.25
29 Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 2007 1.23
30 Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008 1.19
31 Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013 1.16
32 Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol 2003 1.14
33 Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn 2005 1.11
34 Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 2007 1.09
35 A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn 2006 1.08
36 Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer. Ann Diagn Pathol 2004 1.07
37 Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006 1.07
38 Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 2002 1.06
39 Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011 1.05
40 Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol 2014 1.02
41 The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence. Int J Cancer 2013 0.97
42 RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. J Thorac Oncol 2014 0.96
43 Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Cancer 2005 0.96
44 Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004 0.94
45 Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer 2004 0.91
46 Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. Int J Cancer 2009 0.90
47 Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas. Hum Pathol 2005 0.89
48 Next-generation pathology. Am J Clin Pathol 2011 0.89
49 Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol 2003 0.88
50 Splenic marginal zone lymphoma: a case report and review of the literature. Arch Pathol Lab Med 2002 0.88
51 Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol 2002 0.87
52 Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference? J Clin Oncol 2010 0.86
53 The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. Clin Cancer Res 2010 0.85
54 Successful surgical intervention for the management of endocarditis due to multidrug resistant Candida parapsilosis: case report and literature review. Mycopathologia 2011 0.84
55 New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Clin Dermatol 2008 0.83
56 Biomarkers in melanoma: stage III and IV disease. Expert Rev Mol Diagn 2005 0.83
57 Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. J Natl Cancer Inst 2015 0.83
58 A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling. Am J Surg Pathol 2015 0.82
59 Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004 0.82
60 Saving lives with accurate HER2 testing. Am J Clin Pathol 2010 0.81
61 Biomarkers in melanoma: staging, prognosis and detection of early metastases. Expert Rev Mol Diagn 2003 0.81
62 Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. Biomark Med 2011 0.81
63 CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol 2007 0.81
64 Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology 2016 0.80
65 Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Rev Mol Diagn 2003 0.80
66 The time for 3T clinical imaging is now. AJNR Am J Neuroradiol 2004 0.79
67 Multigene predictors in early-stage breast cancer: moving in or moving out? Expert Rev Mol Diagn 2008 0.79
68 Expression of cysteine protease protein 32 in prostatic adenocarcinoma correlates with tumor grade. Arch Pathol Lab Med 2004 0.78
69 Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest 2016 0.77
70 Measuring circulating miRNAs: the new "PSA" for Breast Cancer? Oncologist 2010 0.77
71 HER2 Testing in Gastric/Gastroesophageal Junction Adenocarcinomas: Unique Features of a Familiar Test. Gastrointest Cancer Res 2011 0.77
72 Determination of HER2 gene status by fully automated fluorescence microscopy. Anal Quant Cytol Histol 2011 0.76
73 Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology 2016 0.75
74 Magnetic Resonance Imaging and Computed Tomography of the Brain-50 Years of Innovation, With a Focus on the Future. Invest Radiol 2015 0.75
75 Genomic microarrays in cancer molecular diagnostics: just biomarker discovery tools or future bedside clinical assays? Expert Rev Mol Diagn 2005 0.75
76 Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. Am J Dermatopathol 2017 0.75
77 The spectrum of grossly visible pigmented lesions in the uterine cervix: a prospective study. Int J Gynecol Pathol 2014 0.75
78 Imaging of Spine Trauma. Neurosurgery 2016 0.75
79 Appendiceal mucosal Schwann cell proliferation: a putative histologic marker of appendiceal diverticular disease. Int J Surg Pathol 2013 0.75
80 Emerging cancer diagnostics. "On slide" or "off slide": that is the question. Am J Clin Pathol 2003 0.75
81 Imaging of Degenerative and Infectious Conditions of the Spine. Neurosurgery 2016 0.75
82 Fluid in the flute: Reversible hydromyelia. J Neurol Sci 2005 0.75
83 Improving the accuracy of hormone receptor assays in breast cancer: an unmet medical need. Future Oncol 2005 0.75
84 Prospective observational study of acute postlumbar laminectomy MRI. J Neurosurg Spine 2013 0.75